Antipsychotics

Psychologist and Professor Amber Gum has published the story of her personal journey of rethinking psychotropic medication in a special issue on "The Politics of Mental Health" in The Journal of Medicine and the Person. Influenced by Mad in America and the work of Robert Whitaker, Gum became aware of evidence that “suggests that psychotropic medications are less effective and more harmful than most believe” and now hopes to encourage other mental health professionals and researchers to engage in open-minded, critical self-assessment of standard practices.

Following a lawsuit brought by Andrew Thibault of Parents Against Pharmaceutical Abuse (PAPA), the FDA has produced adverse event and severe adverse event reports...

This study brings awareness to inappropriate continuation of neuroleptic medications beginning in the ICU, or other specialized hospital units that typically downgrade patients and...

Plaintiffs allege that Bristol-Myers Squibb and Otsuka Pharmaceutical failed to warn doctors and patients about the risk for compulsive behaviors when taking the atypical...

“A quick look at drugs or drug uses that later turned out to be risky shows a disturbing trail of ‘bought’ science in major medical...

Revealing the false information provided about psychiatry should cause any thinking person, patient, thought-leader or politician to wonder: “how many otherwise normal or potentially curable people over the last half century of psych drug propaganda have actually been mis-labeled as mentally ill (and then mis-treated) and sent down the convoluted path of therapeutic misadventures – heading toward oblivion?”

In a featured article for Psychiatric Services, psychiatrists from Dartmouth raise the alarm on the increasing numbers of children prescribed dangerous antipsychotic drugs. Despite the fact that data on the safety of long-term use of these drugs in this vulnerable population “do not exist,” the rate of children and adolescents being prescribed antipsychotic drugs have continued to increase over the past fifteen years.

On Monday, the US Supreme Court declined to hear Johnson and Johnson’s final appeal, forcing the company to pay $124 million for the deceptive marketing of the antipsychotic Risperdal. In 2011, South Carolina ordered the company to pay $327 million for pursuing “profits-at-all-costs” in its efforts to persuade doctors to prescribe their drug, but the fine was lowered to $136 million last year. The company had hoped to argue that the remaining penalties constituted an “excessive fine” and was supported by PhRMA, the Washington Legal Foundation, the Cato Institute and the Chamber of Commerce.

“Do they make people less aggressive? Yes, sometimes they do. Will they sedate people? Absolutely. Will they make kids easier to manage? They will,” Robert Whitaker tells Liz Spikol for Philadelphia Magazine. “But I know of no study that shows that medicating these kids long-term will help them grow up and thrive. The developing brain is a very delicate thing. The narrative is that these side effects are mild, and that’s just not true, and that the benefits are well-established, and so often they’re not.”

On his website, Dr. Nardo details the hidden risks and bad science behind the growing practice of using atypical antipsychotics to augment antidepressant treatment for severe depression. The story of Atypical Antipsychotic Augmentation of Treatment Resistant Depression is a “prime example” “to illustrate how commercial interests have invaded medical practice.” “Besides the obvious dangers of the Metabolic Syndrome and Tardive Dyskinesia, these drugs don’t really do what they’re advertised to do – make the antidepressants work a lot better.”

When I wrote Anatomy of an Epidemic, one of my foremost hopes was that it would prompt mainstream researchers to revisit the scientific literature. Was there evidence that any class of psychiatric medications—antipsychotics, antidepressants, stimulants, benzodiazepines, and so forth—provided a long-term benefit? Now epidemiologists at Columbia University and City College of New York have reported that they have done such an investigation about antipsychotics, and their bottom-line finding can be summed up in this way: Psychiatry’s “evidence base” for long-term use of these drugs does not exist.

Researchers from the City College of New York and Columbia University published a study this month testing the hypothesis that people diagnosed with schizophrenia treated long-term with antipsychotic drugs have worse outcomes than patients with no exposure to these drugs. They concluded that there is not a sufficient evidence base for the standard practice of long-term use of antipsychotic medications.

Listen: NPR’s On Point with Tom Ashbrook discusses the new book “Moody Bitches: The Truth About the Drugs You’re Taking, The Sleep You’re Missing, the Sex You’re Not Having and What’s Really Making You Crazy,” by the psychiatrist Julie Holland.

Benedict Carey at the New York Times covers the push for new programs that emphasize supportive services, therapy, school and work assistance, and family education, rather than simply drug treatment.

Experiencing emotional pain is a necessary part of life. Emotional pain often contains valuable lessons to help us on our journeys. We need to make sure we are not numbing our hearts to those that are hurting. We need to de-stigmatize the struggles, joys and pains that come with being human. We need to not just mindlessly pursue happiness - though we might think of that as an inalienable right - and avoid pain. We need to do the only thing that brings true joy: embrace all of life and each other, as we experience together all that makes us human.

“A new study is giving insight into how long-term care patients in the province are progressing — or, in some cases, worsening — over time. It found those living in central Newfoundland are more likely to be given antipsychotic drugs they don't need.”

In a series of experiments in mice, researchers found that the drug risperidone alters gut microbes, which in turn profoundly influence metabolism, weight, and overall health.

A former pharma executive has broken ranks with the industry in a new book by reporting how multiple psychiatrists, schools, and his desperate hopes pressed him to allow higher and higher doses of antipsychotic medications. The result: his 15-year-old son's death from Seroquel.

“Some autistic adults have spent much of their lives with the wrong diagnosis, consigned to psychiatric institutions or drugged for disorders they never had,” Jessica Wright writes in The Atlantic.

The New York Times reports that a growing number of infants and toddlers are being prescribed dangerous psychiatric drugs. “Almost 20,000 prescriptions for risperidone (commonly known as Risperdal), quetiapine (Seroquel) and other antipsychotic medications were written in 2014 for children 2 and younger, a 50 percent jump from 13,000 just one year before.”

The Wall Street Journal highlights a new study that found that off-label medications represent about 12% of drug prescriptions and are resulting in negative...

Martha Rosenberg highlights how the popular antipsychotic Seroquel is a perfect example of how direct-to-consumer advertising made billion dollar blockbuster drugs possible before side-effects...

A “not otherwise specified” (NOS) diagnosis is often used when an individual may have some symptoms related to a psychiatric diagnosis but does not meet enough criteria to warrant a particular diagnosis. A new study, published online ahead of print in Psychiatric Services, reveals that the proportion of mental health visits resulting in such NOS diagnoses rose to nearly fifty percent, and that these diagnoses do not result in more conservative psychiatric drug prescriptions.

With the American Medical Association (AMA) declaring its opposition to direct-to-consumer (DTC) drug advertising, Martha Rosenberg asks, did DTC increase the number of people who have "diseases"?

More than ten-percent of adults in the United States are currently prescribed at least one psychiatric medication but there is currently a lack of research on the prevalence of adverse drug events (ADEs) associated with these prescriptions outside of clinical trials.